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The incidence of left ventricular thrombosis after acute
transmural myocardial infarction has been evaluated with
two-dimensional echocardiography. To assess the pre-
ventive action of early anticoagulation with full-dose
heparin, 90 patients, admitted within 5.2 ± 4.6 hours
after the onset of symptoms of their first episode of acute
myocardial infarction (46 anterior and 44 inferior) , were
prospectively studied. Patients were randomly assigned
either to therapeutic anticoagulation with heparin or to
no anticoagulant therapy. Serial two-dimensional echo-
cardiograms were recorded on the day of admission, the
next day , days 4 to 7 and days 20 to 50 to detect left
ventricular thrombus and to assess global left ventricular
performance.
On the first echocardiogram (10.3 ± 8.0 hours after
the onset of symptoms) no thrombus was visualized. In
44 patients with inferior myocardial infarction (23 re-
ceiving heparin and 21 not receiving heparin) no further
left ventricular thrombus developed. In 46 patients with
The incidence of left ventricular thrombosis during acute
myocard ial infarction was determined in recent prospective
studies (1-4) using serial two-dimensional echocardiog-
raphy. The investigators identified a high risk for left ven-
tricul ar thrombosis in patients with transmural anterior myo-
cardial infarction associated with severe apical wall mot ion
abnormalities . However, the influence of anticoagulant ther-
apy was not specifically addressed. The present study had
two principal aims : I) to dem onstrate whether full-d ose
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anterior myocardial infarction, 21 additional thrombi
developed (45.6%) within 4.3 ± 3.0 days after the acute
event. Thrombus developed in 8 (38%) of 21 patients
receiving heparin, compared with 13 (52%) of 25 pa-
tients not receiving heparin. This difference in ventric-
ular thrombosis was not statisticallysignificant (chi-square
with the Yates correction = 0.76; NS). No difference
was found between the subgroups in terms of clinical
variables, infarct size, hemodynamic impairment, in-
tensity of the inflammatory process and quantitative two-
dimensional echocardiographic and cineangiographic left
ventricular function.
It is concluded that early anticoagulation with hep-
arin reduced by 27% the incidence of lef~ ventricular
thrombus formation in anterior acute transmural myo-
cardial infarction, and this relative risk reduction was
not statistically significant when compared with findings
in the untreated group.
(J Am Coli Cardiol 1986;8:419-26)
heparin anticoagulation might prevent intraventricular
thrombus formation , and 2) to evaluate the role of specific
factor s that can contribute to left ventricular thrombosis . A
prospective randomized trial with therapeutic anticoagula-
tion was initiated in patients hospitalized in the cardiac care
unit within the first hours of an acute myocardial infarction .
Serial two-dimensional echocardiography was performed to
detect and monitor left ventricular thrombus formation and
the effects of anticoagulant therapy .
Methods
Selection of patients. Patients were included in the study
if they had a first acute transmural myocardial infarction,
as evidenced by the following criteria: I) history of chest
pain within 12 hours of admi ssion; 2) electrocardiographic
evidence of Q waves with evolutionary ST-T changes; and
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3) characteristic elevation of serum enzyme creatine kinase
(CK) , glutamic oxaloacetic transaminase and lactic dehy-
drogenase to levels typical of acute infarction. Patients were
excluded when the time between onset of symptoms and
admission to the cardiac care unit was greater than 12 hours
or if they exhibited a contraindication to anticoagulant ther-
apy, had a history of electrocardiographic evidence of prior
myocardial infarction, had nontransmural myocardial in-
farction or were receiving anticoagulant therapy before ad-
mission .
Initial procedures. During the first 3 to 6 days in the
cardiac care unit, all patients had the following: 1) a daily
clinical evaluation of their cardiovascular status according
to the Killip and Kimball classification . 2) A daily 12 lead
electrocardiogram to establish the infarct location and eval-
uate Q waves; leads V7 , v, V9 , V3R, V4R and VsR were
also recorded in patients with inferior myocardial infarction.
3) Serial total serum CK determinations every 4 hours for
48 hours to measure the peak CK value (normal < 70
Il.l/Iiter). The usefulness of this simplified approach to detect
the true peak CK with reasonable accuracy has been pre-
viously reported (5).4) Analy sis of arterial blood pH, partial
pressure of oxygen (Po2) and partial pressure of carbon
dioxide (PC02) as well as measurement of erythrocyte sed-
imentation rate and platelet count. 5) Swan-Ganz catheter-
ization for continuous monitoring of right heart pressures
and thermodilution cardiac output measurement. After the
20th day of infarction, the majority of patients underwent
coronary angiography and right anterior oblique left ven-
tricular cineangiography which yielded end-diastolic vol-
ume, ejection fraction and extent of contraction abnormality
expressed as length of akinetic segment divided by end-
diastolic perimeter.
Echocardiographic studies. In all patients, serial two-
dimensional echocardiograms were recorded on admission
(day 0); the next day (day 1); days 4 to 7, when the patient
was transferred to the postcoronary rehabilitation unit; and
days 20 to 50, when the left ventricular cineangiography
was performed. Two-dimensional echocardiograms were
obtained with a Varian model V3400R phased array sector
scanner, equipped with a 2.25 MHz transducer. Examina-
tions were performed with the patient in a supine and slightly
left lateral position. Systematic examination was performed
including four chamber and two chamber apical views, par-
asternal long- and short-axis views, subcostal views and
nonstandard off-axis views to provide more thorough ex-
amination of the left ventricular apex . Varying sector ori-
entations and differing gain settings were employed to help
distinguish echocardiographic artifacts from a true throm-
bus. The apical views were found the most useful for de-
tecting a thrombus and for analyzing segmental asynergy.
Shallow depth settings of 7 and 15 em in the apical views
were particularly effective for detailed imaging of the apex
and for maintaining good near field resolution. All the stud-
ies were recorded in real time at 30 frames /s on a lVC BR
6400 videotape recorder and were reviewed blindly in real
time, slow motion and stop action modes by two indepen-
dent experienced echocardiographers.
The echocardiograms were interpreted for 1) detection
of left ventricular thrombus, 2) presence and location of
wall motion abnormalities, and 3) computerized assessment
of left ventricular end-diastolic volume and ejection fraction
using the Simpson's rule algorithm and Starling method
based on orthogonal two and four chamber apical views (6) .
A thrombus was defined as a distinct echo-dense mass vi-
sualized in at least two different views within the left ven-
tricular cavity, exhibiting definite borders, originating at a
left ventricular wall and being continuous with but clearly
distinguishable from the endocardial border. To avoid false
positive interpretations, special attention was paid to dis-
tinguish a thrombus from anatomic structures such as pap-
illary muscles, prominent muscle trabeculae, chordal struc-
tures or tangential left ventricular wall (7). Whenever there
was observer disagreement regarding diagnosis , a consensus
was reached.
On admission. patients were randomly assigned to tlVO
groups: one group received full-dose heparin anticoagulant
therapy to maintain the activated partial thromboplastin time
at 1.5 to 2.5 times normal. Heparin was administered in-
travenously by an electric infusion pump for the first 4 to
7 days (mean dose 23,800 ± 4 ,200 Ill/day) and then sub-
cutaneously for 20 to 50 days when left ventricular cine-
ventriculography and coronary arteriography were per-
formed. The other group received no heparin. Whenever
clinically required, patients were given intravenous or oral
nitrates, vasodilating agents, inotropic agents or antiar-
rhythmic drugs.
Statistical analysis. Values are expressed as the mean
± SO. Comparisons between groups were performed with
Student's t test for unpaired data or analysis of variance
when appropriate. The incidence of left ventricular throm-
bosis in the treated and untreated groups was tested with
the chi-square test, using Yates' correction when necessary
and the conventional alpha and beta levels of 5 and 20%,
respecti vely.
Results
Clinical features. Ninety-three patients were studied
prospectively; 3 (3.2 %) of these patients had technically
inadequate echocardiograms and were excluded from further
analysis . The remaining 90 patients consisted of 76 men
and 14 women (mean age 53 .3 ± lOA years) admitted to
the cardiac care unit 5.2 ± 4.6 hours after onset of symp-
toms of a first acute transmural myocardial infarction. Forty-
six patients had an anterior and 44 had an inferior infarction;
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46 patients received heparin and 44 did not. No differences
were found between the treated and untreated groups with
regard to age, sex, time elapsed from onset of symptoms
to admission to cardiac care unit, peak serum CK, Killip
classification, hemodynamic impairment secondary to the
infarct, pulmonary capillary wedge pressure and cardiac
index, two-dimensional echocardiographic end-diastolic
volume and ejection fraction assessed on day 0, dosages of
heparin and other drug treatment apart from heparin.
Echocardiographic findings. On the first two-dimen-
sional echocardiogram recorded 10.3 ± 8.0 hours after the
onset of symptoms, no thrombus was visualized. In 44 pa-
tients with inferior infarction (23 receiving and 21 not re-
ceiving heparin), none had further echocardiographic evi-
dence of left ventricular thrombosis on repeat studies. Severe
hypokinesia or akinesia was always observed in the inferior
wall, but in no case was an inferior aneurysm present. Of
46 patients with anterior myocardial infarction (21 receiving
and 25 not receiving heparin), 21 (45.6%) had echocardio-
graphic findings characteristic of left ventricular thrombosis.
The thrombus was detected in the second echocardiographic
study in 10 patients, in the third study in 10 and in the
fourth study in I, that is, an average of 4.3 ± 3.0 days
after the acute event. The time delay to thrombus devel-
opment was 3.8 ± 3.1 days in treated patients and 4.6 ±
3.1 days in untreated patients (p = NS). All the thrombi
detected with two-dimensional echocardiography were lo-
cated at the apex (apical in 16 and septoapical in 5). Severe
anteroapical wall motion abnormality (either akinesia or
dyskinesia) was noted in all patients and was apparent from
the first study. In particular, early anteroapical dyskinesia
was observed in seven patients, of whom five (71%) de-
veloped thrombosis. This incidence tended to be higher than
in patients without early dyskinesia (16 [41%] of 39), but
the difference did not reach statistical significance.
The thrombus shape was variable: it was flat in 12 pa-
tients (57%), pedunculated and protruding into the left ven-
tricular cavity in 6 (29%) (Fig. I) and mobile in only 3
(14%).
Two patients with a ventricular thrombus exhibited clin-
ically diagnosed systemic embolism (2 [9.5%] of21). One
of them was receiving heparin before the embolization and
one was not. In another patient anticoagulant therapy was
stopped because of gastric hemorrhage.
Thrombus in anterior infarction: clinical features and
role of heparin therapy. The hospital mortality rate in the
group with anterior infarction was 8.7% (4 of 46 patients).
In patients not receiving heparin, therapeutic anticoagulation
(intravenous or subcutaneous heparin) was initiated as soon
as the thrombus was visualized. On repeat echocardio-
graphic study thrombosis resolved in 6 patients and persisted
in the 15 remaining patients. Clinical and laboratory data
for the 46 patients with anterior transmural myocardial in-
Figure 1. Two-dimensional echocardiogram revealing a pedun-
culated apical left ventricular thrombus (arrow) detected on day
7 in a patient included in the study within 6 hours of infarction
and randomized to the heparin treatment group. Orthogonal four
chamber (4C) (left) and two chamber (2C) (right) apical views
are presented. No clinically detectable peripheral embolization
occurred. AO = aorta; LV = left ventricle; RV = right ventricle.
farction, with or without heparin and irrespective of the
development of left ventricular thrombosis, are summarized
in Table I. There was no significant difference between the
groups in any of the variables. The salient characteristics
of the same 46 patients with anterior transmural myocardial
infarction who did or did not develop left ventricular throm-
bosis irrespective of the treatment are summarized in Table
2; no significant differences were found between patients
with or without thrombosis. Table 3 indicates the incidence
of left ventricular thrombosis in treated and untreated pa-
tients. A thrombus developed in 8 (38%) of 21 patients
receiving heparin compared with 13 (52%) of 25 patients
not receiving heparin. This 27% relative risk reduction of
the incidence of ventricular thrombosis was not statistically
significant.
To identify specific variables responsible for the devel-
opment ofthrombosis in anterior infarction, the patient pop-
ulation was divided into four subgroups according to whether
heparin treatment was administered and the presence or
absence of thrombus (Table 4). The results indicate no sig-
nificant differences among the four subsets: clinical vari-
ables, infarct size (number of Q waves and peak serum CK),
hemodynamic impairment (lowest POz, highest pulmonary
capillary wedge pressure, lowest cardiac index and stroke
index), intensity of the inflammatory process (erythrocyte
sedimentation rate and platelet count), quantitative two-di-
mensional echocardiographic left ventricular end-diastolic
volume and ejection fraction assessed on the day of admis-
sion and quantitative cineangiographic function (end-dia-
stolic volume, ejection fraction and extent of asynergy).
None of these variables was found to be a significant cor-
relate of left ventricular thrombosis.
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Table 1. Characteristics of 46 Patients With Anterior Myocardial Infarction
After Randomization
Patients Receiving Heparin Patients Not Receiving Heparin
(n = 21) (n = 25)
Age (yr) 56.7 ± 10.7 (21) 55.4±ll.4 (25)
Ratio male/female (no.) 16/5 22/3
Deaths (no.) 3 I
Q waves (no.) 4.7 ± 1.6 (21) 5.5 ± 1.5 (25)
Worst KK class 1.6 ± 1.0 (21) 1.5 ± 0.8 (25)
Peak CK (lV/ml) 1,219 ± 736 (19) 1,125 ± 348 (23)
P0 2 (mm Hg) 70.8 ± 11.1 (18) 69.2 ± 11.5 (24)
PCWP (mm Hg) 18.8 ± 9.0 (20) 19.7 ± 7.6 (24)
CI (liters/min per rrr') 2.48 ± 0.66 (19) 2.53 ± 0.43 (24)
SI (ml/m') 31.6 ± 12.7 (19) 31.3 ± 7.4 (24)
2DE EDV (rnl/rrr') 62.8 ± 15.7 (21) 60.5 ± 13.5 (25)
2DE EF (%) 39.0 ± 9.8 (21) 47.2 ± 9.2 (25)
Angio EDV (ml/rrr') 88.9 ± 33.0 (15) 87.5 ± 24.1 (16)
Angio EF (%) 39.5 ± 11.8 (15) 45.3 ± 10.0 (16)
Angio ACS (%) 34.1 ± 16.5 (15) 24.2 ± 13.7 (16)
Erythrocyte sedimentation 50.1 ± 43.7 (19) 66.8 ± 35.8 (23)
rate (mmlh)
Platelet count (103) 333 ± 152 (19) 321 ± 121 (23)
No statistically significant difference was found between the groups for any variable. Numbers in parentheses
indicate number of patients measured. ACS = abnormal contracting segments; Angio = angiographic; CI =
cardiac index; CK = creatine kinase; EDV = end-diastolic volume; EF = ejection fraction; KK = Killip
and Kimball; PCWP = pulmonary capillary wedge pressure; P0 2 = partial pressure of oxygen; SI = stroke
index; 2DE = two dimensional echocardiography.
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Discussion
Incidence of left ventricular thrombosis in acute myo-
cardial infarction. This study confirms that patients with
anterior transmural infarction and severe apical wall motion
abnormality represent a high risk group for left ventricular
thrombosis. In our study, apical akinesia or dyskinesia was
noted with two-dimensional echocardiography in all of the
46 patients with anterior infarction, and a thrombus devel-
oped in 21 of them, an incidence of 45.6% which compares
favorably with previously reported data (1-4,8). A left ven-
tricular thrombus may develop very soon after myocardial
infarction (4.3 ± 3.0 days after the acute event in the current
study) and sometimes within the first 20 to 72 hours (1,3,9).
The rarity of left ventricular thrombosis in the setting of
inferior myocardial infarction was also confirmed because
no thrombus developed in 44 such patients in our study.
The incidence was also 0% in the study by Asinger et al.
(1), whereas I (2%) of 41 patients in McEntee's series (10)
and 2 (1.5%) of 131 patients in Weinreich's series (4) had
left ventricular thrombus with inferior myocardial infarc-
tion. Thrombosis can develop in an inferior wall aneurysm,
but its incidence is much lower than that in anterior myo-
cardial infarction (11,12).
Heparin against development of left ventricular
thrombosis. One major finding of the current prospective
randomized study is the lack of a definite protective effect
of very early therapeutic anticoagulation with heparin against
development of left ventricular thrombosis in acute trans-
mural anterior myocardial infarction. The incidence of
thrombosis was 38% in the treated group and 52% in the
untreated group, a difference not statistically significant when
compared with findings in the patients not treated with hep-
arin. The incidence of thrombus formation was higher in
patients with early dyskinesia (71%), but this trend did not
reach statistical significance, possibly because of the small
sample size of this subset of patients (n = 7) in our study.
These findings contrast with the dramatic reduction of the
frequency of thrombus formation with early anticoagulant
therapy recently demonstrated in a study by Nordrehaug et
al. (13): no thrombus in 24 treated patients in comparison
with 7 thrombi in 21 untreated patients. In their series, a
short period of 24 hours of heparin infusion followed by
oral warfarin for 10 days seemed to yield as good results
as the intravenous thrombolytic regimen used by Eigler et
al. (9). On the other hand, several unrandomized studies
(8,14) demonstrated the development of left ventricular
thrombus in patients with acute anterior infarction despite
adequate early anticoagulant therapy. Furthermore, Sharma
et al. (15), in a recent uncontrolled study, observed that
intracoronary streptokinase therapy followed by heparin did
not seem to influence thrombus formation in acute infarc-
tion.
Considering that the randomization in our series was
lACC Vol. 8, No.2
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Table 2. Characteristics of 46 Patients With Anterior Myocardial Infarction With and Without
Left Ventricular Thrombosis (LVT)
Patients With LVT Patients Without L VT
(n = 21) (n = 25)
Age (yr) 56.0 ± 9.4 (21) 56.0 ± 12.4 (25)
Ratio male/female (no.) 19/2 19/6
Deaths (no.) 3 I
Q waves (no.) 5.5 ± 1.3 (2 ]) 4.8 ± 2.2 (25)
Worst KK class 1.6 ± 1.0 (21) 1.5 ± 0.8 (25)
Peak CK (IU/mI) 1.291 ±604 (21) 1,043 ± 479 (2\)
P0 2 (rnrn Hg) 67.2 ± 10.8 (20) 73.0 ± 11.2 (22)
PCWP (mm Hg) 20.5 ± 7.9 (21) 18.3 ± 8.4 (23)
CI (liters/min per rrr') 2.46 ± 0.44 (21) 2.68 ± 0.69 (22)
SI (ml/nr') 30.9 :': 8.5 (21 ) 32.0 :': 11.7 (22)
2DE EDV (ml/m') 63.0 :': 12.6 (21 ) 60.3 :': 15.9 (25)
2DE EF (%) 43.4 ± II. I (21 ) 43.6 ± 9.7 (25)
Angio EDV (mllm 2) 87.6 ± 24.7 ( 15) 88.11 .z, 32.5 (16)
Angio EF (%) 41.8 ± 10.0 (15) 43.5 ± 12.6 (16)
Angio ACS (%) 30.3 ± 12.5 (15) 27.0 :!. 19.0 (16)
Erythrocyte sedimentation 70.3 ± 32.7 (19) 50.6 ± 42.9 (23)
rate (rnrn/h)
Platelet count (10') 346 ± 155 (18) 312 ± 118 (24)
Heparin dosage (Ie/day) 24.750 ± 5,520 (8) 24,160 ± 3,880 (13)
Abbreviations and significance as in Table I.
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successful (no significant differences between treated and
untreated groups), particularly with regard to markers of
infarct size, hemodynamic impairment and left ventricular
function assessed by two-dimensionalechocardiographyand
cineangiography, at least three questions must be discussed:
I) the validity of two-dimensional echocardiography for
detecting left ventricular thrombi, 2) the appropriateness of
the heparin dosage used, and 3) the sample size of the current
study.
Validity of echocardiography for detecting left ven-
tricular thrombus. Identificationof left ventricular throm-
bus by two-dimensional cchocardiography has been well
documented (16-18), and published data (19) show that
when compared with anatomic study this technique has a
sensitivity of 77% and specificity of 93%. Because equiv-
Table 3. Incidence of Left Ventricular Thrombosis (LVT) in
Treated (Heparin +) and Untreated (Heparin -) Patients in 46
Patients With Anterior Myocardial Infarction
Total
LVT + LVT - Patients
Heparin + 8 (38%) 13 (62%) 21
Heparin - 13 (52%) 12 (48%) 25
Total patients 21 25 46
Difference 14%; X~ = 0.76 (NS)
Yo = chi square with the Yates correction.
ocal cchocardiograms were shown by Stratton et al. (20) to
be most likely falsely positive for thrombus (71% of cases),
specificity slightly increases but sensitivity decreases when
the equivocal studies are considered as negative. Finally.
because the apex is not always well visualized, some echo-
cardiographic studies must be excluded as technically in-
adequate-3.2% in the current study compared with 2.7%
in the study of Asinger et al. (I). Considering all advantages
and disadvantages, two-dimensional echocardiography is
probably the most convenient and the most widely used
technique for detecting left ventricular thrombosis. espe-
cially when repeat studies are needed at the patient's bedside
in a cardiac care unit during the early phase of acute myo-
cardial infarction.
Appropriateness of heparin dosages used. Despite well
conducted early anticoagulant therapy in our study, the pro-
tective effect of heparin against left ventricular thrombus
formation was found to be incomplete in anterior myocardial
infarction. Conventional heparin dosages were used (23,800
± 4,200 IU/day) and the activated partial thromboplastin
time was at 1.5 to 2.5 times the normal level in all the
treated patients. Furthermore. the mean dosage of heparin
administered was similar in those with anterior infarction
with or without thrombus (24,750 ± 5,500 and 24,200 ±
3,900 IU/day, respectively) as well as in those with anterior
and inferior infarction (24,200 ± 4,400 and 23,100 ±
4, 100 IU/day, respectively); the latter group never devel-
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Table 4. Classification of the 46 Patients Into Four Subgroups According to the Treatment Received and the Development
of Thrombus
H + T + H + T - H - T + H - T -
Age (yr) 58.7 :t 10.8 55.5 :t 10.9 54.3 :t 8.5 56 .7 :t 14.2
Q waves (no.) 4. 9 :t 1.1 4.6 :t 1.9 5.9 :t 1.3 5.0 :t 1.7
KK class 1.9 :t 1.2 1.4 :t 0.9 1.5 :t 1.0 1.4 :t 0.7
Peak CK (IU1ml) 1.393 :t 919 1.093 :t 587 1.229 :t 323 989 :t 346
Po2 (mm Hg) 66.5 :t 11.5 74.3 :t 10.0 66.4 :t 10.3 7 1.9 :t 12.3
PCWP (mm Hg) 22.2 :t 9.7 16 .5 :t 8.0 19 .4 :!: 6.8 20. 2 :t 8.9
CI (liters/min per m2) 2.2 :t 0.3 2.6 :t 0 .8 2.6 :t 0 .5 2.5 :t 0.4
SI (ml/m2) 28.9 :t 9.9 33.3 :t 14.4 32 .0 :!: 7.3 30.2 :t 7.8
20E EOV (ml/rrr') 62.4 :t 9.4 62 .9 :!: 18.6 63.2 :!: 14.3 57.5 :t 12.3
20 E EF (%) 38.7 ± 13.0 39.1 ± 8.3 46.0 :t 9.6 48 .5 ± 8.9
Angio EOV (rnl/rrr') 82.4 :t 30.4 93.0 :!: 35.9 90 .2 ± 22.7 82.0 :!: 28.6
Angio EF (%) 37.6 ± 12.5 40 .7 ± 12.1 43 .9 ± 8.4 48.0 ± 13.5
Angio ACS (%) 34.8 ± 13. I 33.6 ± 19 .2 28.1 ± 12.3 16.4 ± 14.4
Sedimentation rate (mmlh) 64.8 ± 47.2 43.3 ± 42.3 72 .8 ± 27 .5 60.0 :t 44 .1
Platelet count (103) 325 :t 186 338 :!: 137 360 ± 139 286 :t 94
No statistically significant correlations were found between any of these variables and left ventricular thrombus formation within the four subgroups.
H + or H - = heparin received or not received. respectively; T + or T - = development of thrombus or no development of thrombus. respectivel y;
other abbreviations as in Table J.
oped left ventricular thrombosis. Several studies (21- 23)
demon strated that coagulation patterns during myocardial
infarction are characterized by enhanced fibrin formation.
In particular, in a recent study Mombelli et al. (24) measured
plasma fibrinopeptide A levels as an index of fibrin for-
mation before and after anticoagulant therapy , and their data
suggest that in acute infarction higher than con ventionally
employed doses of heparin may be requi red to fully inhibit
thrombin formation. Such a hypothesis was not examined
when our study was designed and measurement of plasma
fibrinopeptide A concentration was not performed. This test
cannot be proposed as a routine to adapt the heparin dosage
levels in all patients with acute myocardial infarction. In
addition , use of high dose s of heparin to maintain the ac-
tivated thromboplastin time at greater than 2. 5 times normal
would increase the risk of bleeding compli cations .
Was the sample size adequate? As in all apparentl y
negat ive studies, the number of patients in each group of
the trial might not have been large enough to detect a mean-
ingful therapeutic effect that actually exists. Generally, de-
tecting a small difference betwee n the treatment groups re-
quires a larger sample size than detecting a large difference.
Howe ver , different investigators may disagree about a clin-
ically significant difference for a given trial. If one assumes
a natural incidence of 40 to 50% of left ventricular throrn-
bosis in anterior infarction as suggested by several reports
(1-4,8 ), recently published nomograms (25) could help de-
termine whether the sample size of the current randomized
study is adequate , depending on the differences believed to
be clinically meaningful. If one expects almost no left ven-
tricular thrombosis with heparin , only a very small sample
size would be required. On the other hand , the number of
patients in our study would not be large enough and the
negat ive results would be unacceptable to a clinician con-
fident of a partial protective effect of heparin against throm-
bus formation , assum ing the yet to be proven hypothesis
that the observed 27% relative risk reduction of left ven-
tricular thrombu s formation will remain stable when the
sample size increases . Further studies with more patients
would be needed to reach an eventual statistical significanc e.
Infarct size, hemodynamic impairment and left ven-
tricular thrombosis. This study did not identify any spe-
cific factor that influences left ventricular thrombus for-
mation in high risk patients represented by those with acute
transmural anterior infarction . Blood stasis may be pro-
moted by apical akinesia or dyskinesia and significant left
ventricular dysfunct ion may favor the appearance of mural
thrombu s . Severe apical wall motion abnormalities were
invariably present in this subset of patient s, but no corre-
lations were found between left ventr icular thrombu s for-
mation and infarct size or hemodynamic impairment. Infarct
size was assessed by the number of Q waves and peak serum
CK. None of these variables was significantly different in
these subgroups, in accord with the observations of Asinger
et al. ( I) and Kothari et al . (3) . Left ventricular performance
assessed by early two-dimensional echocardiography and
late cineangiographic ejection fraction was found equall y
depre ssed in all subgroups. Two reports (3, 8) showed sig-
nificantly lower radionu clide ejection fraction in patient s
with infarction with thrombus, but their data pooled anterior
and inferior infarctions, although the latter is rarely asso-
ciated with mural thrombosis.
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Congestive heart failure is closely related to infarct size
in patients without prior infarction. However, as in the study
by Asinger et al. (l ), no correlation was found between
clinical KiIIip and Kimball functional classification and
thrombus formation. Furthermore, we performed a more
accurate and objective assessment of heart failure by con-
tinuous monitoring of hemodynamics and blood gas anal-
ysis, but no significant relation between cardiac index, pul-
monary capillary pressure, P02 and mural thrombosis was
seen. Simple routine laboratory tests were used to evaluate
the intensity of the inflammatory syndrome (sedimentation
rate, platelet count and plasma fibrinogen level). No cor-
relations were found between these variables and left ven-
tricular thrombus formation,
Conclusions. Early anticoagulant therapy is presumed
to reduce the incidence of arterial and venous thromboem-
bolism and to prevent mural thrombus formation in patients
with acute infarction. Our study failed to demonstrate a
significant reduction of left ventricular thrombosis by full-
dose heparin anticoagulation. None of the routinely per-
formed clinical tests provided a rationale to explain mural
thrombus development, which remains to be elucidated.
One cannot exclude the possibility that further trials with
more patients could yield a significant relation, Similarly
one cannot exclude either the possibility that patients with
anterior myocardial infarction, characterized by enhanced
fibrin formation, may develop a coagulopathy that could be
influenced to a minor degree by conventional dosage anti-
coagulant therapy; such a study was beyond the scope of
this randomized trial. The protective effect of heparin was
found to be incomplete and left ventricular thrombus did
develop in 8 of our 21 patients with acute anterior transmural
infarction despite well conducted early heparin therapy as
judged by conventional tests. The inability of heparin to
prevent left ventricular thrombus formation in our study does
not imply its inefficiency in preventing systemic embolism.
Because embolization was not the end point of the current
trial, therapeutic anticoagulation was initiated as soon as
the thrombus was detected in those patients who were not
receiving heparin.
The benefits of treating all patients with heparin remain
to be conclusively established, and thus the clinician needs
to be able to select those who are at higher risk of subsequent
thrombosis for consideration of early treatment. From a
practical point of view, the incidence of left ventricular
thrombosis in patients with anterior infarction associated
with early dyskinesia is very high and may allow one to
recommend heparin therapy in this clinical setting, Whether
the benefit of such a policy is worth the risk of drug-induced
hemorrhage remains to be tested in further clinical trials.
On the other hand, prophylactic full-dose heparin therapy
does not seem to be useful in patients with inferior infarc-
tion.
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